Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06420440 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06420440 · ClinicalTrials.gov record · last posted 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

StatusRecruiting
PhasePhase 2
Started2024-06-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 1, 2025 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2024-05-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-04-28
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06420440
Lead Sponsor Chen Xiaoping
Conditions HCC
Enrollment 160 participants
Start Date 2024-06-01
Primary Completion 2026-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-01